Drugs Made In America Acquisition DMIIR
NASDAQ DMIIR
$0.07 -0.01 (-7.04%)
As of: Sep 2, 2026 · 12:48 PM EDT

Drugs Made In America Acquisition (DMIIR) Non Operating Income (2025 - 2026)

Drugs Made In America Acquisition (DMIIR) posted quarterly Non Operating Income of $4.6 million for Q4 2025, up 4075.47% quarter-over-quarter from $109355.0 in Q3 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Drugs Made In America Acquisition (DMIIR) Non Operating Income (2025 - 2026) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has reported Non Operating Income for 1 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.

Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Cluster Group Holdings 8.00 Bn 8.00 Bn - -
2 Agriculture & Natural Solutions Acquisition 853.42 Mn 853.17 Mn - -
3 K&F Growth Acquisition 836.15 Mn 836.15 Mn - 2.68 Mn
4 Armada Acquisition 665.60 Mn 665.55 Mn - -
5 Pioneer Acquisition I 652.11 Mn 914.54 Mn - -
6 Oxley Bridge Acquisition 652.11 Mn 652.11 Mn - -
7 Titan Acquisition 651.43 Mn 941.85 Mn - -
8 GSR IV Acquisition 622.22 Mn 622.22 Mn - -
9 Launch One Acquisition 618.70 Mn 618.70 Mn - 2.19 Mn
10 Drugs Made In America Acquisition 5.10 Mn 5.10 Mn - 4.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.51 Mn
Dec 31, 2025 4.57 Mn
Sep 30, 2025 109,355.00